IsoRay Medical has supplied the first set of Cesium-131 brachytherapy seeds for the purpose of furthering research and development in cancer therapy.

Cs-131 is currently approved by Health Canada for the treatment of low-risk prostate cancers and has been cleared by the FDA for the treatment of a wide variety of cancers such as prostate, head and neck, brain, breast, lung and eye, according to the company.

IsoRay, in conjunction with its Canadian distribution partner, Inter V Medical, plans to seek approvals for Cs-131 for a variety of malignant disease states.

The Richland, Wash.-based company recently tested the Cs-131 implant for the treatment of colorectal cancer in the U.S.